文献速递妇科

哪些因素可预测非高危早期宫颈癌患者辅助治疗的有效性?KGOG-1028 的辅助分析

Which factors predict the effectiveness of adjuvant treatment in patients with non-high-risk early-stage cervical cancer? Ancillary analysis of KGOG-1028.
PubMed 文献 · Gynecol Oncol · 2025-03-25

该回顾性队列研究利用韩国妇科肿瘤学组-1028 数据,纳入 2000 至 2008 年诊断的 2018 FIGO IB1-IIA 期宫颈癌患者(低危 1109 例、中危 360 例),采用逆概率治疗加权平衡混杂因素后分析辅助治疗对无病生存的影响。结果显示,淋巴血管间隙浸润阳性、深 1/3 间质浸润和肿瘤大小 >4 cm 的患者可从辅助治疗中获益,而非鳞状细胞癌组织学患者未获益。

要点

  • 淋巴血管间隙浸润阳性患者接受辅助治疗可延长无病生存(HR=0.37;95%CI 0.23-0.60)。
  • 深 1/3 间质浸润患者接受辅助治疗可延长无病生存(HR=0.29;95%CI 0.17-0.49)。
  • 肿瘤大小 >4 cm 患者接受辅助治疗可延长无病生存(HR=0.28;95%CI 0.11-0.70);非鳞癌患者未获益(HR=0.69;95%CI 0.41-1.16)。

核心结论

  • 非高危早期宫颈癌患者若存在淋巴血管间隙浸润阳性、深 1/3 间质浸润或肿瘤大小 >4 cm,可从辅助治疗中获益,但非鳞状细胞癌组织学患者未获益。

研究设计与样本

  • 回顾性队列研究,利用韩国妇科肿瘤学组-1028 数据,纳入 2000 至 2008 年诊断的 2018 FIGO IB1-IIA 期宫颈癌患者,包括低危 1109 例和中危 360 例。
  • 在特定预后因素(淋巴血管间隙浸润、1/3 间质浸润、肿瘤大小 >4 cm 或非鳞状细胞癌)限制的患者中评估辅助治疗对无病生存的影响,并使用逆概率治疗加权平衡辅助治疗组与未治疗组的临床病理因素。

主要发现

  • 低危患者中 281 例(25.2%)接受辅助治疗,中危患者中 261 例(72.5%)接受辅助治疗。
  • 在未接受辅助治疗组中,淋巴血管间隙浸润阳性、深 1/3 间质浸润、肿瘤大小 >4 cm 和腺癌组织学具有显著预后意义。
  • 辅助治疗可延长淋巴血管间隙浸润阳性患者的无病生存(HR=0.37;95%CI 0.23-0.60)。
  • 辅助治疗可延长深 1/3 间质浸润患者的无病生存(HR=0.29;95%CI 0.17-0.49)。
  • 辅助治疗可延长肿瘤大小 >4 cm 患者的无病生存(HR=0.28;95%CI 0.11-0.70);但对非鳞状细胞癌组织学患者无效(HR=0.69;95%CI 0.41-1.16)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify predictive factors for the effectiveness of adjuvant therapy (AT) in patients with non-high-risk early-stage cervical cancer. METHODS: A retrospective cohort study was conducted using data from the Korean Gynecologic Oncology Group-1028, which included 1109 low-risk and 360 intermediate-risk patients diagnosed with 2018 FIGO stage IB1-IIA cervical cancer from 2000 to 2008. Disease-free survival (DFS) according to AT was evaluated in restricted patients with certain prognostic factors, such as lymphovascular space invasion (LVSI), depth of invasion (DI) of 1/3, tumor size >4 cm, or nonsquamous cell carcinoma (non-SCC). In addition to the prognostic factor of interest, clinicopathologic factors were balanced between the AT-naïve and AT groups using the inverse probability of treatment weighting. RESULTS: AT was administered to 281 (25.2 %) low-risk patients and 261 (72.5 %) intermediate-risk patients. Positive LVSI, DI of deep 1/3, tumor size >4 cm, and adenocarcinoma histology were significantly prognostic when tested in the AT-naïve group. AT was effective in prolonging DFS in patients with positive LVSI (hazard ratio [HR] = 0.37; 95 % CI, 0.23-0.60), DI of deep 1/3 (HR = 0.29; 95 % CI, 0.17-0.49), and tumor size >4 cm (HR = 0.28; 95 % CI, 0.11-0.70). However, AT was not effective in patients with non-SCC histology (HR = 0.69; 95 % CI, 0.41-1.16). CONCLUSIONS: Patients with non-high-risk early-stage cervical cancer with any of the following conditions, including positive LVSI, DI of deep 1/3, and tumor size >4 cm, can benefit from AT but not those with non-SCC histology.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kim J, Jang J, Lim MC, et al. Which factors predict the effectiveness of adjuvant treatment in patients with non-high-risk early-stage cervical cancer? Ancillary analysis of KGOG-1028. Gynecol Oncol. 2025. PMID: 40139056. doi:10.1016/j.ygyno.2025.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。